Dengue vaccine’s Phase 1 trial receives approval from manufacturer

0
9

A top official announced on Tuesday that THE INDIAN Immunologicals Limited (IIL), a prominent vaccine producer in the nation, has received approval for a Phase-1 trial of the dengue vaccine.

Dr. K. Anand Kumar, Managing Director of IIL, said in a statement to The Indian Express on the sidelines of the World Dairy Summit in Greater Noida: “We have now received authorization for Phase-1 (trial) for dengue (vaccine). Yesterday, the authorization arrived. Dengue does not currently have a vaccine (in India). This will be a significant turning point. The licence to conduct human trials has now been given after the conclusion of all animal experiments.

According to Kumar, the National Institute of Health in the United States and the IIL are working together to develop a dengue vaccine (NIH). He said, “They gave us the virus.

When questioned about the start date of the Phase-1 trial, Kumar responded, “The centres have already been designated for trial,” expressing the optimism that the vaccine would be available within the following two years.

Two further dengue vaccine candidates are being developed, according to official records, by Panacea Biotec Limited and Sanofi India Private Limited. Both have been given the go-ahead for clinical testing. Phase 1 and Phase 2 trials have been completed by Panacea Biotec Limited.

The vaccine developed by Sanofi India Private Limited has already received US approval, and trials there have begun.

In the nation last year, there were 1,93,245 cases of dengue and 346 fatalities, according to the National Center for Vector Borne Diseases Control (NCVBDC).

Animal and human vaccinations are produced by the IIL, a National Dairy Development Board subsidiary. It is one of the two suppliers of the goat pox vaccine, which is being used to protect cattle from lumpy skin disease.

In August of this year, the IIL increased goat pox vaccine manufacturing from 1 million doses in July to over 10 million doses. According to Kumar, the IIL previously distributed 2–3 million doses of the goat pox vaccine each year. The vaccination costs Rs 5 per dosage.

Read This |Alerts that your dengue infection might be growing worse
Kumar responded, “We are in talks with Agrinnovate India,” when asked about the indigenous lumpy skin vaccination created by the Indian Council of Agricultural Research (ICAR). Today is the first meeting. Agrinnovate India is the commercialization arm for goods and innovations created by the ICAR institutes. We will question them about the vaccine data and other pertinent facts.

Lumpi-ProVacInd vaccine was jointly produced by two ICAR institutions, the Indian Veterinary Research Institute (IVRI) in Izatnagar, Uttar Pradesh, and the National Research Centre on Equines (NRCE) in Hisar, Haryana.

According to Department of Animal Husbandry sources, as of September 11 this year, 16.42 lakh cattle in 197 districts across 13 states had the lumpy skin condition. According to sources, 7.5,000 animal deaths from the disease were documented as till September 11; 9.96 lakh cattle recovered, while 5.5 lakh still had active cases. According to sources, 1.10 crore doses of the vaccine had been given out as of September 11th. The Indian Immunologicals Limited (IIL), a major vaccine producer in the nation, has received approval for a Phase-1 study of the dengue vaccine, a top official announced on Tuesday.

Dr. K. Anand Kumar, Managing Director of IIL, said in a statement to The Indian Express on the sidelines of the World Dairy Summit in Greater Noida: “We have now received authorization for Phase-1 (trial) for dengue (vaccine). Yesterday, the authorization arrived. Dengue does not currently have a vaccine (in India). This will be a significant turning point. The licence to conduct human trials has now been given after the conclusion of all animal experiments.

According to Kumar, the National Institute of Health in the United States and the IIL are working together to develop a dengue vaccine (NIH). He said, “They gave us the virus.

When questioned about the start date of the Phase-1 trial, Kumar responded, “The centres have already been designated for trial,” expressing the optimism that the vaccine would be available within the following two years.

Two further dengue vaccine candidates are being developed, according to official records, by Panacea Biotec Limited and Sanofi India Private Limited. Both have been given the go-ahead for clinical testing. Phase 1 and Phase 2 trials have been completed by Panacea Biotec Limited.

The vaccine developed by Sanofi India Private Limited has already received US approval, and trials there have begun.

In the nation last year, there were 1,93,245 cases of dengue and 346 fatalities, according to the National Center for Vector Borne Diseases Control (NCVBDC).

Animal and human vaccinations are produced by the IIL, a National Dairy Development Board subsidiary. It is one of the two suppliers of the goat pox vaccine, which is being used to protect cattle from lumpy skin disease.

In August of this year, the IIL increased goat pox vaccine manufacturing from 1 million doses in July to over 10 million doses. According to Kumar, the IIL previously distributed 2–3 million doses of the goat pox vaccine each year. The vaccination costs Rs 5 per dosage.

Kumar responded, “We are in talks with Agrinnovate India,” when asked about the indigenous lumpy skin vaccination created by the Indian Council of Agricultural Research (ICAR). Today is the first meeting. Agrinnovate India is the commercialization arm for goods and innovations created by the ICAR institutes. We will question them about the vaccine data and other pertinent facts.

Lumpi-ProVacInd vaccine was jointly produced by two ICAR institutions, the Indian Veterinary Research Institute (IVRI) in Izatnagar, Uttar Pradesh, and the National Research Centre on Equines (NRCE) in Hisar, Haryana.

According to Department of Animal Husbandry sources, as of September 11 this year, 16.42 lakh cattle in 197 districts across 13 states had the lumpy skin condition. According to sources, 7.5,000 animal deaths from the disease were documented as till September 11; 9.96 lakh cattle recovered, while 5.5 lakh still had active cases. According to sources, 1.10 crore doses of vaccination have been given out as of September 11.